Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2021 / Oct / On Cloud Cas9?
Glaucoma Research & Innovations

On Cloud Cas9?

Using “CRISPR interference” to combat TGFβ2-induced ocular hypertension

By Geoffrey Potjewyd 10/21/2021 1 min read

Share

CRISPR-Cas9 has had a whirlwind impact on gene editing; the versatile method of targeting specific DNA strands even winning the 2020 Nobel Prize in Chemistry. And, of course, the technique hasn’t been overlooked by the field ophthalmology; ocular diseases with clear genetic drivers of pathology are prime targets for such genetic manipulation – and one such example is primary open angle glaucoma (POAG), where elevated TGFβ2 expression contributes to increased IOP through pathological changes in the trabecular meshwork (TM). Researchers from the Indiana University School of Medicine in Indianapolis, USA, screened for the optimal genetic sequence to inhibit TGFβ2 expression – and proved its utility in human TM cells and in a mouse model of TGFβ2-induced ocular hypertension (1). Clearly, such “CRISPR interference” can only be used to treat POAG when elevated TGFβ2 expression plays a role – but will this proof of concept mean that surgeons increasingly switch from the scalpel to the molecular scissors?

References

  1. MP Rayana et al., Invest Ophthalmol Vis Sci, 62, 7 (2021). PMID: 34499703.

About the Author(s)

Geoffrey Potjewyd

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

More Articles by Geoffrey Potjewyd

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: